The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Current treatment outcome of hilar cholangiocarcinoma

간문부 담관암의 최근 치료 성적

  • Dong, Seok-Ho (Department of Gastroenterology and Hepatology, Kyung Hee University School of Medicine)
  • 동석호 (경희대학교 의학전문대학원 소화기내과학교실)
  • Published : 2010.12.01
⟨ Previous Next ⟩

Abstract

Cholangiocarcinoma (CC) is one of the most lethal cancers defying long-term control of disease. Hilar cholangiocarcinoma (Klatskin tumor) which occur at the confluence of right and left hepatic ducts are getting special attention for these tumors due to difficult management. Surgical treatment of hilar cholangiocarcinoma remains difficult and most of patients are diagnosed when unresectable. The 5-year survival rate after curative resection was 20~40% with median survival of 12~16 months. In those patients with unresectable hilar CC, liver failure and recurrent sepsis secondary to biliary obstruction occupy substantial proportion of cause of death. For most of these patients endoscopic or percutaneous biliary drainage provides effective palliation. Palliative chemotherapy and radiation therapy either alone or in combination have been relatively ineffective for unresectable cholangiocarcinoma. A photodynamic therapy is an emerging palliative treatment that seems to provide pain relief, improve biliary patency and increase survival. In addition to these options, newly developed target therapies are promising, but still experimental treatment. Liver transplantation in combination with neoadjuvant chemoradiation therapy seems to be an option for a highly selected group of patients. The development of new therapeutic options and multimodal promising combinations of the palliative therapeutic options is expected to improve the health-related quality of life and prolong the overall survival.

Keywords

References

  1. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features. Am J Med 38:241-256, 1965 https://doi.org/10.1016/0002-9343(65)90178-6
  2. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 15:4240-4262, 2009 https://doi.org/10.3748/wjg.15.4240
  3. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 344:1655-1660, 1994 https://doi.org/10.1016/S0140-6736(94)90455-3
  4. Lai EC, Chu KM, Lo CY, Fan ST, Lo CM, Wong J. Choice of palliation for malignant hilar biliary obstruction. Am J Surg 163:208-212, 1992 https://doi.org/10.1016/0002-9610(92)90102-W
  5. Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 47: 354-362, 1998 https://doi.org/10.1016/S0016-5107(98)70218-4
  6. Deviere J, Baize M, de Toeuf J, Cremer M. Long-term follow-up of patients with hilar malignant Stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 34:95-101, 1988 https://doi.org/10.1016/S0016-5107(88)71271-7
  7. Park J, Kim MH, Kim KP, Park do H, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3:298-305, 2009 https://doi.org/10.5009/gnl.2009.3.4.298
  8. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 230:663-671, 1999 https://doi.org/10.1097/00000658-199911000-00008
  9. Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, Katoh H. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospeilar cstudy. Ann Surg 240:95-101, 2004 https://doi.org/10.1097/01.sla.0000129491.43855.6b
  10. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 238:720-727, 2003 https://doi.org/10.1097/01.sla.0000094437.68038.a3
  11. Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, Carey LC, Rosemurgy AS. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 190:810-815, 2005 https://doi.org/10.1016/j.amjsurg.2005.07.025
  12. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507-517, 2001 https://doi.org/10.1097/00000658-200110000-00010
  13. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 9:43-57, 2004
  14. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224:463-473; discussion 473-475, 1996 https://doi.org/10.1097/00000658-199610000-00005
  15. Forsmo HM, Horn A, Viste A, Hoem D, Ovrebo K. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 7:412-417, 2008
  16. Todoroki T, Kawamoto T, Koike N, Takahashi H, Yoshida S, Kashiwagi H, Takada Y, Otsuka M, Fukao K. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 87:306-313, 2000 https://doi.org/10.1046/j.1365-2168.2000.01343.x
  17. Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B, Larson D, Nagorney DM. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 139:514-523, 2004 https://doi.org/10.1001/archsurg.139.5.514
  18. Song GW, Lee SG, Lee YJ, Park KM, Hwang S, Kim KH, Ahn CS, Moon DB, Ha TY, Ryu JH, Park JI, Lee HJ. Analysis of survival predictors after surgical resection of hilar cholangiocarcinoma (HCCC) in a single institute with large volume. Korean J Hepatobiliary Pancreat Surg 11:32-39, 2007
  19. Jang JY. Clinical outcome of surgical treatment for Klatskin tumor. Korean J Pancreas Biliary Tract 14:130-134, 2009
  20. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patiens. Transplantation 69:1633-1637, 2000
  21. Kaiser GM, Sotiropoulos GC, Jauch KW, Lohe F, Hirner A, Kalff JC, Konigsrainer A, Steurer W, Senninger N, Brockmann JG, Schlitt HJ, Zulke C, Buchler MW, Schemmer P, Settmacher U, Hauss J, Lippert H, Hopt UT, Otto G, Heiss MM, Bechstein WO, Timm S, Klar E, Holscher AH, Rogiers X, Stangl M, Hohenberger W, Muller V, Molmenti EP, Fouzas I, Erhard J, Malago M, Paul A, Broelsch CE, Lang H. Liver transplantation for hilar cholangiocarcinoma: a German survey. Transplant Proc 40:3191-3193, 2008 https://doi.org/10.1016/j.transproceed.2008.08.039
  22. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242:451-458, 2005
  23. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 47:644-649, 2000
  24. Thongprasert S. Therole of chemotherapy in cholangiocarcinoma. Ann Oncol 16(Suppl 2):ii93-ii96, 2005
  25. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?: a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685-1695, 2002 https://doi.org/10.1002/cncr.10831
  26. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 13:1470-1479, 2009 https://doi.org/10.1007/s11605-009-0900-0
  27. Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 27:173-179, 2003
  28. Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 35:548-552, 2005 https://doi.org/10.1007/s00595-005-2989-4
  29. Stein DE, Heron DE, Rosato EL, Anne PR, Topham AK. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy . Am J Clin Oncol 28:21-23, 2005 https://doi.org/10.1097/01.coc.0000139017.90599.f5
  30. Itoh H, Nishijima K, Kurosaka Y, Takegawa S, Kiriyama M, Dohba S, Kojima Y, Saitoh Y. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci 50:2231-2242, 2005 https://doi.org/10.1007/s10620-005-3040-8
  31. Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46:581-587, 2000 https://doi.org/10.1016/S0360-3016(99)00472-1
  32. Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 54:414-419, 2002 https://doi.org/10.1016/S0360-3016(02)02952-8
  33. Serafini FM, Sachs D, Bloomston M, Carey LC, Karl RC, Murr MM, Rosemurgy AS. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 67:839-843; discussion 843-844, 2001
  34. Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, Hurwitz HI, Bendell JC, Morse MA, Clough RW, Czito BG. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73:148-153, 2009 https://doi.org/10.1016/j.ijrobp.2008.07.008
  35. Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, Donehower RC, Laheru DA, Hruban RH, Abrams RA. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 68:178-182, 2007 https://doi.org/10.1016/j.ijrobp.2006.11.048
  36. Figueras J, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, Rafecas A, Torras J, Jaurrieta E. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl 6:786-794, 2000 https://doi.org/10.1053/jlts.2000.18507
  37. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH. Effects of 5- fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23:425-428, 2000 https://doi.org/10.1097/00000421-200008000-00023
  38. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14:2311-2315, 1996 https://doi.org/10.1200/JCO.1996.14.8.2311
  39. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9:653-656, 1998 https://doi.org/10.1023/A:1008241008379
  40. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 87:702-704, 2002 https://doi.org/10.1038/sj.bjc.6600543
  41. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 60:321-328, 2007 https://doi.org/10.1007/s00280-006-0380-9
  42. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783-789, 2001
  43. Lee GW, Kang JH, Kim HG, Lee JS, Lee JS, Jang JS. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 29:127-131, 2006 https://doi.org/10.1097/01.coc.0000203742.22828.bb
  44. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332-2338, 2005 https://doi.org/10.1200/JCO.2005.51.008
  45. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramontuc O, uvete F. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GER OR study. Ann Oncol 15:1339-1343, 2004 https://doi.org/10.1093/annonc/mdh351
  46. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896-902, 2007 https://doi.org/10.1038/sj.bjc.6603648
  47. Ohnishi H, Asada M, Shichijo Y, Iijima N, Itobayashi E, Shimura K, Suzuki T, Yoshida S, Mine T. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology 42:265-268, 1995
  48. Cameron JL, Pitt HA, Zinner MJ, Kaufman SL, Coleman J. Management of proximal cholangio carcinomas by surgical resection and radiotherapy. Am J Surg 159:91-97; discussion 97-98, 1990 https://doi.org/10.1016/S0002-9610(05)80612-9
  49. Ishii H, Furuse J, Nagase M, Kawashima M, Ikeda H, Yoshino M. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology 51:954-957, 2004
  50. Golfieri R, Giampalma E, Renzulli M, Galuppi A,Vicenzi L, Galaverni MC, Cappelli A. Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo 20:757-760, 2006
  51. Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, Miyamoto N. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 57:1357-1365, 2003 https://doi.org/10.1016/S0360-3016(03)00770-3
  52. Kuvshinoff BW, Armstrong JG, Fong Y, Schupak K, Getradjman G, Heffernan N, Blumgart LH. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 82:1522-1525, 1995 https://doi.org/10.1002/bjs.1800821122
  53. Zhu AX, Meyerhardt JA, Balszkowsky LS, Muzikansky A, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Sahani DV. Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) and oxaliplatin (OX). J Clin Oncol 27(Suppl 15):4578, 2009 [Abstract] https://doi.org/10.1200/JCO.2009.22.0442
  54. Gruenberger B, Schueller J, Tamandl D, Kaczirek K, Schernthaner G, Gruenberger T. K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study. J Clin Oncol 27(Suppl 15):4586, 2009 [Abstract]
  55. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mossner J. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 31:291-298, 2000 https://doi.org/10.1002/hep.510310205
  56. Cheon YK, Cho YD, Baek SH, Cha SW, Moon JH, Kim YS, Lee JS, Lee MS, Shim CS, Kim BS. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol 44:280-287, 2004
  57. Ortner ME, Caca K, Berr F, LiebetruthJ, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mossner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125:1355-1363, 2003 https://doi.org/10.1016/j.gastro.2003.07.015
  58. Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C, Mössner J, Hauss J, Witzigmann H. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 97:2783-2790, 2003 https://doi.org/10.1002/cncr.11401